TG Therapeutics, Inc. announced that its existing term loan facility agreement with Hercules Capital, Inc. has been amended to increase the size of the facility to $200 million, with $70 million funded at closing. Under the terms of the amendment, the size of the term loan facility was increased to $200 million, with $70 million available and drawn at closing on December 30, 2021. The remaining $130 million may be drawn at the Company's option, in three subsequent tranches.

The first tranche is available upon U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA)/Biologics License Agreement (BLA) for the combination of ublituximab and umbralisib (referred to as “U2”) for the treatment of chronic lymphocytic leukemia (CLL), the second tranche is available upon FDA approval of the BLA for ublituximab for the treatment of relapsing forms of multiple sclerosis (RMS), and the third tranche is available to fund future initiatives, subject to the approval of the Hercules Investment Committee.